Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market. Key therapies that we expect to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb) as well as the targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), and Zynlonta (ADC Therapeutics); also, approval of bispecific antibodies Lunsumio (Roche), Epkinly / Tepkinly (Genmab / AbbVie), and Columvi (Roche) will drive growth. We also expect the noncovalent BTK inhibitor Jaypirca (Loxo Oncology / Eli Lilly) for CLL / SLL and combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) to enter the CLL market, causing a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of other bispecific antibody—odronextamab (Regeneron Pharmaceuticals), antibody-drug conjugate brentuximab vedotin (Seagen) etc. will further fragment the FL, CLL / SLL, DLBCL, and MCL patient settings, creating intense competition.

Questions Answered

  • What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2022-2032 forecast period, by geography?
  • What is the market impact of label expansions of CAR T-cell therapies in earlier lines of R/R DLBCL? What is the expected market impact of other drug approvals in various NHL / CLL patient populations?
  • Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target?
  • What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?

Content Highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase III / PR: 4+ drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports